Summary Brief Abstract Citation ASN.1 MEDLINE XML UI List LinkOut Related Articles Cited in Books Domain Links 3D Domain Links GEO DataSet Links Gene Links Genome Links GEO Links Nucleotide Links OMIM Links PMC Links Cited in PMC PopSet Links Protein Links SNP Links Structure Links UniSTS Links  Show: 5 10 20 50 100 200 500 Sort Author Journal Pub Date Text File Clipboard E-mail Order

1: Ther Drug Monit. 1996 Oct;18(5):581-5.

Related Articles, Links

Bupropion plasma levels and CYP2D6 phenotype.

Pollock BG, Sweet RA, Kirshner M, Reynolds CF 3rd.

Department of Psychiatry, University of Pittsburgh School of Medicine, Pennsylvania, USA.

All available antidepressants with the exception of fluvoxamine and nefazodone either are metabolized by cytochrome P450 2D6 (CYP2D6) and/or inhibit this isozyme. To date, nothing in this regard has been published concerning bupropion. We report that plasma level/dose ratios for bupropion, and its metabolites erythrohydrobupropion and threohydrobupropion, were not associated with debrisoquine metabolic status in 12 patients, three of whom were poor 2D6 metabolizers. The plasma level/dose ratios for the metabolite hydroxybupropion were, however, significantly higher in poor 2D6 metabolizers. In three patients, who received a second phenotyping test during treatment with bupropion, debrisoquine metabolic ratios were not increased. It is thus inferred that bupropion is neither metabolized by nor inhibits CYP2D6. The potential accumulation of hydroxybupropion after CYP2D6 inhibition may, however, contribute to toxicity and impair bupropion's therapeutic effectiveness.

Publication Types:

• Clinical Trial

PMID: 8885123 [PubMed - indexed for MEDLINE]

Jan 29 2004 15:06:34